MediWound Addresses Emergency Demand for NexoBrid to Treat Burn Casualties in Israel

MediWound Ltd., a leading biopharmaceutical company specializing in next-generation enzymatic therapeutics for tissue repair, has taken swift action to address the urgent demand for its product, NexoBrid, in treating burn casualties resulting from the war in Israel. Hospitals and military forces have reached out to MediWound, urgently requesting supplies of NexoBrid to aid the significant number of burn victims.

In response to this critical need, MediWound has deployed all available inventory of NexoBrid to support the treatment of these burn victims. The company remains committed to fulfilling its obligations to global markets and is implementing measures to ensure a continuous supply of NexoBrid.

NexoBrid is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and/or full-thickness thermal burns without harming viable tissue. It has been approved in over 40 countries, including the United States, European Union, and Japan, where it has been designated as an orphan biologic drug.

MediWound’s dedication to developing innovative solutions for non-surgical tissue repair is evident through its focus on providing rapid and effective biologics that improve patient experiences and outcomes while reducing costs and unnecessary surgeries. NexoBrid, the company’s first drug, is an FDA-approved orphan biologic that can replace surgical interventions for eschar removal in severe burns, minimizing associated costs and complications.

MediWound’s commitment to research and development is further demonstrated by its pipeline, which includes EscharEx, a Phase III-ready biologic for debridement of chronic wounds. EscharEx offers significant advantages over the current monopoly legacy drug, presenting an opportunity to expand the market. Additionally, the company’s pipeline includes MW005, a topical therapeutic for the treatment of basal cell carcinoma, which has shown promising results in a recently completed Phase I/II study.

For more information on MediWound and its innovative enzymatic therapeutics, please visit www.mediwound.com and follow the company on LinkedIn.